CTLA4 and neoplasm: This successful conversion therapy reflects the potential additive or synergistic effects of the treatment regimen: CTLA-4 inhibition expanded the tumor-specific T cell clonotype repertoire and PD-1 blockade maintained the cytotoxic activity of effector T cells (33).